NASDAQ$ZURA
Zura Bio Limited · Q2 2024 earnings
Q2 2024 earnings · · Before market open · Investor relations
Briefing
Zura Bio Limited reported a net loss of $26.3 million for the second quarter of 2026 driven by increased R&D spending on its tibulizumab programs.
The clinical-stage biotech company posted a net loss of $26.3 million for the three months ended June 30, 2026, compared with $16.0 million in the prior-year quarter. Research and development expenses rose sharply to $20.7 million as the company advanced Phase 2 trials in hidradenitis suppurativa and systemic sclerosis. Cash and cash equivalents stood at $205.1 million following the February 2026 equity offering.
- Net loss widened to $26.3 million as R&D expenses more than doubled year-over-year to $20.7 million.
- Cash position strengthened to $205.1 million after raising $134.6 million in the February 2026 equity offering.
- Enrollment completed in both TibuSHIELD (HS) and TibuSURE (SSc) Phase 2 studies with topline data expected in Q4 2026 and H1 2027, respectively.
- Basic and diluted EPS was $(0.21) on 126.8 million weighted-average shares outstanding.
Headline financials
Revenue & EPS history
Zura Bio · Revenue · Quarterly
$0
Forward guidance
Topline results from the TibuSHIELD Phase 2 HS study are expected in the fourth quarter of 2026; TibuSURE Phase 2 SSc study topline expected in the first half of 2027. A Phase 2 study in polymyalgia rheumatica is planned to start by year-end 2026.
Tailwinds
- Strong cash position supports ongoing clinical development through at least 2028.
- Phase 2 enrollment targets exceeded in both ongoing tibulizumab studies.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports
-1.2%
Avg return
Earnings day
-2.4%
Avg return
5 days after
-3.1%
Avg return
30 days after
36%
4 / 11 earnings
Positive
+22.8%
Q4 2023
Best reaction
-26.0%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q3 2026 | -3.2% | -2.9% | -30.5% | |
| Q4 2025 | -9.5% | -17.3% | -13.2% | |
| Q2 2025 | +6.9% | +8.8% | +25.8% | |
| Q1 2025 | -7.6% | -14.2% | +0.0% | |
| Q4 2024 | +4.0% | +5.3% | -33.0% | |
| Q1 2024 | -0.6% | +9.6% | -14.9% | |
| Q4 2023 | +22.8% | +26.3% | +90.1% | |
| Q3 2023 | +2.8% | -1.2% | -4.2% | |
| Q2 2023 | -0.6% | -1.2% | +1.8% | |
| Q1 2023 | -26.0% | -28.5% | -3.0% | |
| Q4 2022 | -1.8% | -11.4% | -52.5% | |
| Q3 2022 | — | — | — | |
| Q2 2022 | — | — | — | |
| Q1 2022 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro